United Kingdom, Independent Pharmacist October 2, 2023

Chapel Pharmacy in Farnborough, led by its manager James Martin, won the Pharmacy Innovation award. One innovation stood out for the judges.

Before Covid, Chapel Pharmacy caught the attention of Dr. de Verteuil, a GP with special interests in valve disease, who recognised their innovative approach and successful track record with previous pilots.

Consequently, the pharmacy was chosen to undertake a pioneering pilot aimed at early detection and diagnosis of valve disease within the local community. Employing a digital stethoscope coupled with AI technology, eMurmur, Martin and his team performed auscultations on eligible patients in the pharmacy.

For more information, visit https://www.independentpharmacist.co.uk/news/independents-celebrated-at-independent-pharmacy-awards

Jungingen, Germany (PRWeb) November 26, 2021

Rudolf Riester and eMurmur® are pleased to announce that they have collaborated to create a new standard in heart and lung auscultation.

Riester’s Ri-sonic® digital stethoscope provides crisp, clear sound quality. Coupled with the power of eMurmur’s incredible platform for digital auscultation, it allows caregivers to obtain clear live sounds and recordings, creating a complete solution for listening to the body in-person and remotely like never before.

“We are very pleased to be collaborating with eMurmur on such an exciting project. Ri-sonic and eMurmur enable remote auscultation and subsequent diagnosis with state-of-the-art quality sound for heart, lungs and bowel. We are confident that this will help millions of patients to receive timely and professional advice and will empower MCPs to monitor the development of their patients over time to better treat and care for them. Telemedicine is expanding its remits beyond the current context of a global pandemic. Ri-Sonic and eMurmur bring a new degree of precision and accuracy in primary care for better screening and diagnosis of heart and lung disease. And more importantly, done in real time,” says Irina Zhdanova, Managing Director at Rudolf Riester.

The ability to perform remote auscultation during telehealth visits between the patient and caregiver adds a new dimension to the treatment pathway. Patients can get faster access to expert assessments while removing the burden of travel and time off work. Providers can reduce unnecessary referrals and get patients the care they require faster.

“By building the eMurmur platform, we are bringing auscultation into the 21st century. Going digital, creating heart and lung sound records, and enabling tele-auscultation and e-consultations are game changing milestones in auscultation, especially with the challenges the pandemic has presented to providers,” explained Andreas Schriefl, PhD, founder and CEO of eMurmur. “We at eMurmur are experts in driving and delivering such innovation, Riester is a trusted industry leader in building high-quality stethoscopes with decades of experience and a global reach. It is a proud moment for eMurmur to have Rudolf Riester as a partner and ultimately patients will benefit from the improved patient care our solution delivers.”

The collaboration has allowed the expertise in Riester’s 60 years of producing high quality stethoscopes to be coupled with the entrepreneurial excellence and know-how of the team at eMurmur. The outcome – innovation and expertise create a new dawn for auscultation.

About Rudolf Riester
Riester is a company with a proud history of excellence. Based in Juningen, Germany and developing the highest quality diagnostic medical devices since 1948. At Riester, we have a no compromise approach. German quality at its best. Reliability, from research and development to quality control and production of the highest standards.
In 2007 Riester was acquired by Halma plc, transforming Riester from a family-owned business, into being part of an international group of companies. Through trust and partnership, Riester has developed a global reach, offering products to over 150 countries world-wide. ​For more information, visit: https://www.riester.de/

Sugar Land, Texas (PRWeb) November 18, 2021
MobilDrTech, Inc. is proud to announce its’ selection by eMurmur as a US Distributor for their latest commercially available digital stethoscope platform, eMurmur. The product is available immediately from MobilDrTech for medical providers, telemedicine equipment and service providers, hospitals, health systems and third-party payers. Marketed versions include Basic, Pro, Telehealth and Enterprise levels and pricing schedules.

eMurmur is an innovative, digital auscultation platform, tested and proven in top academic medical centers. It employs advanced engineering to enable listening to the entire body with clarity greatly valued by even the most highly trained ear. The software facilitates the use of the most widely used telemedicine stethoscopes over the Internet, enabling recording and streaming from iOS and Android mobile devices, as well as Windows and Mac-based computers and laptops via a browser-based portal.

According to Nat Gist, President of MobilDrTech, “Having worked with telemedicine stethoscopes for over 15 years, I was immediately impressed with the capability and potential for the eMurmur open platform in telemedicine. Customers have long searched for ways to use various digital stethoscopes with iOS and Android mobile devices in addition to laptops and PCs. We are very excited to be selected as a US distributor.”

Andreas Schriefl, PhD, founder and CEO of eMurmur states: “We are very pleased to partner with MobilDrTech as a US Distributor for eMurmur. We have been impressed with their extensive knowledge of the telemedicine market and with their record of outstanding customer service. I am certain they will contribute greatly to our success.”

About MobilDrTech
MobilDrTech, Inc. is a distributor of telehealth and telemedicine software, diagnostic devices and telehealth platforms. Founded in 2009, MobilDrTech represents leading manufacturers of telemedicine equipment and developers of telehealth-specific software. The company markets and sells a comprehensive line of telemedicine products including telemedicine stethoscopes, otoscopes, dermascopes, general examination cameras, telemedicine carts and vital signs monitoring devices for remote patient monitoring (RPM) and chronic care management (CCM). For more information, visit http://www.mobildrtech.com

eMurmur®, a technology partner to the global healthcare community, announces the world’s first open software platform for advanced digital auscultation (stethoscope technology) is now available in the US. It makes improved screening for heart, lung, and bowel health accessible to hardware and telehealth providers throughout the US. The eMurmur platform is hardware neutral and runs on iOS, Android, and common browsers, making it the first open and widely accessible auscultation technology. Healthcare providers can use it with their existing digital stethoscope, enabling them to better screen, monitor, and diagnose.

Heart and lung disease are leading causes of death globally for both men and women. Auscultation (meaning “to listen with a stethoscope”) is a 200+ year-old method to screen for heart and lung disease by listening for abnormal sounds, used worldwide for patients of all ages. It’s an integral step in providing primary care. eMurmur has modernized this traditional technology to improve outcomes for physicians and patients.

“The eMurmur platform allows healthcare providers to listen to the human body with a degree of clarity greatly valued by even the most highly trained ear. Our technology can be used in-person, remotely, or asynchronously to screen patients for early warning signs related to heart, lung, and bowel health.” said Andreas Schriefl, founder and CEO of eMurmur. “What makes eMurmur unique is that we are an open platform for third party digital stethoscopes and telehealth providers. We are increasingly seeing new innovative stethoscopes coming to market and welcome them to use our world class auscultation software to access our cutting-edge capabilities.”

eMurmur is also pleased to announce its US distribution partner MobilDrTech Inc. Anyone interested in a free trial of the eMurmur software can download the iOS or Android app. MobilDrTech sells a variety of compatible digital stethoscopes and offers demos of the eMurmur platform.

“The appetite for advanced healthcare technologies that support virtual consultations and offer a high degree of confidence in early heart, lung and bowel screening is in demand,” said Nat Gist, MobilDrTech Inc. “The pandemic has made telehealth a critical part of our healthcare system and working with eMurmur to bring this potentially lifesaving technology and open platform to the US market means that more Americans will benefit from early detection and receive the high-quality healthcare they deserve.”

eMurmur’s digital records enable providers to evaluate patient conditions over time, as well as consult with colleagues outside of the examination setting. Using advanced engineering, eMurmur makes it possible for healthcare providers to screen, monitor, diagnose, and consult on heart, lung and bowel irregularities with greater certainty.

ST. PAUL, Minn. and OTTAWA, Canada, Dec. 18, 2020 /PRNewswire/ -- Becoming skilled in auscultation requires practice and repeated exposure to real patient heart and lung sounds. In response to that need, 3M™ Littmann® Stethoscopes has joined forces with eMurmur® to release two new branded apps – one to support students and the other designed for instructors.
The collaboration between 3M Littmann Stethoscopes and eMurmur has resulted in mobile apps that help early-career clinicians master critical auscultation skills while also supporting instructors as they train those students.

"As a trusted industry leader, Littmann Stethoscopes was one of the first to introduce a learning app more than five years ago," explained Kristi Barnett, Sr. Director, 3M Medical Devices. "We know that for clinicians, listening is a critical skill for making accurate diagnoses. Ensuring clinicians master this skill and supporting instructors as they teach auscultation is the intent of these new apps. With the challenges that remote learning has presented during the pandemic, continued access to recordings of real patient auscultation sounds and remote teaching capabilities will be of even greater benefit to both students and instructors. With the Littmann Learning App and Littmann University App, we take listening and learning to a new level."

The Littmann Learning App combines intensive repetition with continued learning and testing to prepare a clinician for real-world patient care. Studies show that students need continued access to learning material outside of the classroom as they can gradually lose their auditory training if they stop listening to heart sounds. Offering a learner access to repeated self-testing is also key as it facilitates the use of a mastery learning model for clinical skill acquisition.

For instructors, the Littmann University App supports remote classroom capabilities, enabling live streaming of a large library of patient sounds, as well as group testing with immediate results.

"We are a leader in AI-powered digital auscultation technology and teaching solutions. Partnering with 3M Littmann Stethoscopes allows us to expand our educational solutions beyond their current capabilities and offer them to students, instructors and clinicians worldwide," said Andreas Schriefl, co-founder and CEO, eMurmur. "We understand that being able to confidently assess heart sounds can help improve cardiac care and is a skill that the new Littmann Apps – powered by eMurmur – can help teach. These two apps offer a powerful pairing for learning."

3M™ Littmann® Stethoscopes is a global leader in auscultation technology - providing innovative solutions to improve patient care. Littmann stethoscopes are trusted worldwide for precision, acoustic excellence, reliable design, and exceptional performance, helping clinicians detect difficult-to-hear body sounds and improve patient outcomes.

We are pleased to be part of the Creative Destruction Lab's Super Session 2019.

Creative Destruction Lab's Super Session is a two day event featuring keynote speakers, networking and a showcase of CDL's graduating early-stage tech companies.

eMurmur® announced today that its flagship "eMurmur ID" solution has received the CE mark certification. Accreditation is an important part of the eMurmur business, which now carries the quality management certification ISO 13485:2016 and the EC certification according to the Medical Devices Directive 93/42/EEC. The news comes on the heels of eMurmur ID receiving FDA clearance, making it the only heart murmur detection solution that has received clearance for both the U.S. and European markets.

eMurmur ID is a mobile and cloud solution which operates in conjunction with a 3rd party electronic stethoscope. It uses advanced machine learning to identify and classify pathologic and innocent heart murmurs, the absence of a heart murmur, and S1, S2 heart sounds. The end-to-end solution is comprised of ML-based analytics, a mobile app, and a web portal. It supports the workflows of healthcare providers performing cardiac auscultation and has multiple applications including primary and specialty care, and corporate health.

Heart Murmur Detection: Past vs Future
Heart disease is the leading cause of death globally for both men and women, causing over 30% of all deaths annually. Heart auscultation (meaning "to listen with a stethoscope") is a 200+ year-old method to screen for heart disease by listening for abnormal heart sounds (murmurs), used worldwide for patients of all ages. However, heart auscultation is subjective in nature and studies have shown that accuracy rates amongst primary care providers are low. With an accuracy rate of over 85%, eMurmur ID makes expert-level auscultation accessible to any healthcare provider performing auscultation.

Early Access Program
The eMurmur ID technology has multiple areas of application including HMO networks, point of care clinics, executive health, pre-physicals, retail clinics, occupational health, rural health and telemedicine. eMurmur launched an early access program available at https://emurmur.com/clinical, designed to give early adopters full access to eMurmur ID.

Learn more here: https://www.prnewswire.com/news-releases/emurmur-receives-ce-mark-certification-for-its-heart-murmur-detection-solution-300866398.html

May 7, 2019

eMurmur® today announced that it has received FDA clearance, enabling a new era in heart murmur detection. eMurmur ID is a mobile and cloud solution which operates in conjunction with a 3rd party electronic stethoscope. It uses advanced machine learning to identify and classify pathologic and innocent heart murmurs, the absence of a heart murmur, and S1, S2 heart sounds. The end-to-end solution is comprised of AI-based analytics, a mobile app, and a web portal (all HIPAA compliant). It supports the workflows of healthcare providers performing cardiac auscultation and has multiple applications including primary and specialty care, and corporate health.

Heart Murmur Detection: Past vs Future
Heart disease is the leading cause of death globally for both men and women, causing 31% of all deaths annually. Heart auscultation (meaning “to listen with a stethoscope”) is a 200+ year-old method to screen for heart disease by listening for abnormal heart sounds (murmurs), used worldwide for patients of all ages. However, heart auscultation is subjective in nature and studies have shown accuracy rates amongst primary care providers to be as low as 20-25%. With an accuracy rate of over 85%, eMurmur ID makes expert-level auscultation accessible to any healthcare provider performing auscultation.

“The eMurmur ID solution has the potential to disrupt medical care”, said Dr. Derek Exner, Professor and Canada Research Chair in Cardiovascular Clinical Trials at the University of Calgary. “The evidence for its utility is solid and includes five studies on over 1000 patients, including blinded, multi-centre trials. This system has been shown to be accurate, informative, and easy-to-use. It provides healthcare professionals with a potent screening tool and method to confirm their clinical diagnoses, enhancing patient care.”

“Receiving FDA clearance marks a significant milestone in our company’s history, and I’m very excited to finally be able to take the eMurmur ID solution to market,” said Andreas Schriefl, co-founder and CEO of eMurmur. “We believe that eMurmur ID has the potential to disrupt the status-quo of heart murmur screening and significantly reduce costs to healthcare systems worldwide.”

“From a technology perspective, receiving FDA clearance requires solid clinical proof of the algorithm performance characteristics, as well as a quality and risk management system that ensures patient safety and compliance with stringent regulatory standards,” said Andreas Reinisch, co-founder and CTO of eMurmur. “Through this process, our company has gained significant knowledge and expertise to facilitate and support future AI- based medical solutions,”

About eMurmur (www.emurmur.com)
Founded in 2014, eMurmur is a privately-held medical technology company specializing in Machine Learning for the analysis of data for medical applications. eMurmur is the leader in automated heart murmur detection technology and has completed multiple prospective clinical studies in this field, demonstrating expert-level accuracy rates. In addition, the company’s intellectual property includes a proprietary database of 1000s of heart recordings with corresponding gold-standard echocardiogram diagnoses and cardiologist assessments. eMurmur also provides heart-auscultation educational solutions to leading medical schools. The company is headquartered in Ottawa, Canada (CSD Labs® International), has R&D operations in Graz, Austria (CSD Labs®), and does business under the name eMurmur.

For media or commercial inquiries, visit www.emurmur.com/contact

Today, eMurmur announced the release of eMurmur Heartpedia, an app designed to help patients, parents and medical professionals to better understand heart defects through anatomically-correct 3D models and corresponding heart and murmur sound recordings for each defect. eMurmur Heartpedia is a major upgrade of the original Heartpedia app from Cincinnati Children’s Hospital Medical CenterCentre which has been downloaded over 100,000 times since its release in 2014.

"Congenital heart defects can be difficult to visualize, understand, and explain. Supplying easy-to-understand information on heart defects and established surgical repair strategies can result in improved comprehensive care for the patient,” says Peace Madueme, MD MS FAAP FACC FASE at Nemours Children’s Hospital in Orlando. "eMurmur Heartpedia is unique in that it provides validated patient heart sounds, 3D cardiac models and videos in an easy- to- use app that is accessible and understandable by anyone."

“The rich visual and audio heart information in eMurmur Heartpedia make it much easier to understand heart defects, which we expect will be invaluable to families, healthcare professionals, medical and nursing schools.” says Andreas Schriefl, founder and CEO of eMurmur

eMurmur Heartpedia is a downloadable app that runs on a mobile device such as a smartphone or tablet, and is available from both the IOS and Android app stores. Check out eMurmur Heartpedia in the Google Play and Apple App store.

eMurmur announced today that it has successfully graduated from the Creative Destruction Labs (CDL), a highly competitive and successful seed-stage program for massively scalable, science-based companies. eMurmur participated in the 9-month program as part of the CDL-West’s health stream.

eMurmur announces that renowned cardiologist, Dr. Derek Exner, Professor has joined its advisory board. Dr. Exner is Canada Research Chair, Cardiovascular Clinical Trials; Associate Dean, Clinical Trials, Cumming School of Medicine; and Professor, Department of Cardiac Sciences and Community Health Sciences, University of Calgary.

eMurmur announced today that it has incorporated in Canada and opened an office in Ottawa to address the North America market in order to begin to build out its sales, marketing and market development team. eMurmur will continue to operate and grow its R&D facilities in Graz, Austria.

eMurmur announces Andrew Redington, MD, an internationally renowned cardiologist and Chief of Pediatric Cardiology at Cincinnati Children’s Hospital in Ohio, United States, joins the company as a medical advisor.
Read more on Business Wire

eMurmur announces that Lillian Lai, MD, Cardiologist at Children's Hospital of Eastern Ontario, Canada joins the company as a medical advisor. Dr. Lai previously served as a Principal Investigator on several clinical studies for the development and validation of the eMurmur technology.

eMurmur approved to receive up to EUR 600,000 in Seed financing from the Austrian government, aimed to help transform well formulated business ideas around innovative technologies into a start-up ready for market entry.

The European Commission awards a prestigious EUR 50,000 Horizon 2020 grant to eMurmur to advance its R&D into a clinically tested mobile-based technology for the objective detection and classification of heart murmurs.

eMurmur wins the special MedTech award at the seventh international business plan competition "Best of Biotech". The competition awards excellence in the areas of life science and medical technology, is organised by Austria Wirtschaftsservice and commissioned by the Austrian Federal Ministry of Science, Research and Economy. A total of 30 projects with economic potential from six countries were selected by an international jury comprised of experts from the fields of industry, finance and economics. eMurmur was awarded a prestigious prize worth EUR 10,000.

CSD Labs® GmbH (d.b.a. eMurmur) was formally founded in Graz, Austria with the vision of leveraging state-of-the art signal processing, machine learning, and high quality clinical datasets to create an autonomous heart murmur detection AI. Additionally, eMurmur raises EUR 420,000 from US angel investors.

Founders Andreas Schriefl (PhD Physicist / Biomedical Engineer) and Andreas Reinisch (Computer Science & Biomedical Engineer) receive a prestigious start-up grant of EUR 210,000 from the Austrian government, rewarded to promising high-tech ideas with high-growth potential to allow for preliminary feasibility work on heart sound analysis and development of a business plan around the founders’ vision.